Bristol-Myers Squibb Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD 14.31 B

Bristol-Myers Squibb Company Operating Cash Flow is USD 14.31 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 4.27% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Bristol-Myers Squibb Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 13.72 B, a 12.27% change year over year.
  • Bristol-Myers Squibb Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 12.22 B, a -24.52% change year over year.
  • Bristol-Myers Squibb Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 16.20 B, a 15.83% change year over year.
  • Bristol-Myers Squibb Company Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 13.98 B, a 32.27% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities